-
All
-
Info
-
Investment
-
IPO
IPO
HCmed Innovations Co., Ltd., one of our portfolio companies, has been listed on Taiwan Stock Exchange.
-
Listed on Feb. 2, 2026
-
TWSE：6934
Info
Satoshi Motomura, Daiwa Corporate Investment's Head of Taipei Representative Office, contributes to Nikkei Biotechnology & Business: "Behind Taiwan’s burgeoning biotech industry is a diverse pool of skilled professionals."
LINK
Info
Satoshi Motomura, Daiwa Corporate Investment's Head of Taipei Representative Office, contributes to The Nikkei: "Taiwan’s biotech gains momentum with a continued run of IPOs and growing interest from Japan."
LINK
Info
Satoshi Motomura, Daiwa Corporate Investment's Head of Taipei Representative Office, contributes to Nikkei Biotechnology & Business: "Public and private sectors joining forces: Taiwan’s investment-driven path to becoming an innovation nation."
LINK
Info
EirGenix Inc., one of our portfolio companies, has been listed and traded on the Taiwan Stock Exchange.
Info
Satoshi Motomura, Daiwa Corporate Investment's Head of Taipei Representative Office, contributes to Nikkei Biotechnology & Business: "The government fund behind Taiwan's biotech growth: a toolbox of tactics."
LINK
Info
Satoshi Motomura, Daiwa Corporate Investment's Head of Taipei Representative Office, contributes to Nikkei Biotechnology & Business: "Action-driven and speed-focused: what we can learn from Taiwanese management."
LINK
IPO
PRISM BioLab Co.,Ltd., one of our portfolio companies, has been listed on Tokyo Stock Exchange.
-
Listed on Jul. 2, 2024
-
TSE Growth：206A
Info
Satoshi Motomura, Daiwa Corporate Investment's Head of Taipei Representative Office, contributes to Nikkei Biotechnology & Business: "Why do Taiwanese startups have such high market caps?"
LINK
Info
Yuka Niimi has been ranked 5th in the "Japan's Venture Capitalist of the Year" by Forbes JAPAN (a Japanese edition of "The Midas List" by Forbes).
LINK
IPO
K Pharma, Inc., one of our portfolio companies, has been listed on Tokyo Stock Exchange.
-
Listed on Oct. 17, 2023
-
TSE Growth：4896
IPO
Noile-Immune Biotech Inc., one of our portfolio companies, has been listed on Tokyo Stock Exchange.
-
Listed on Jun. 28, 2023
-
TSE Growth：4893
Info
APRINOIA Therapeutics Inc. has entered into a definitive agreement for a business combination with Ross Acquisition Corp II, a SPAC founded by Mr. Wilbur Ross who is a prominent investor and the former Commerce Secretary of the United States.
LINK
Investment
We have established Surv BioPharma Inc., a biotech company.
IPO
TMS Co., Ltd., one of our portfolio companies, has been listed on Tokyo Stock Exchange.
-
Listed on Nov. 22, 2022
-
TSE Growth：4891
Info
The fund size of Daiwa Taiwan-Japan BioVenture Investment Limited Partnership II has been increased to 15.3 billion JPY.
Info
DCI Partners has been adopted as a certified venture capital firm by the Japan Agency for Medical Research and Development (AMED), as a participant of AMED's program to support biotech startups and strengthen the ecosystem.
LINK
Info
The fund size of Daiwa Taiwan-Japan BioVenture Investment Limited Partnership II has been increased to 14.5 billion JPY.
IPO
Renascience Inc., one of our portfolio companies, has been listed on Tokyo Stock Exchange.
-
Listed on Sep. 24, 2021
-
TSE Mothers：4889
Info
We have established Daiwa Taiwan-Japan BioVenture Investment Limited Partnership II.
IPO
StemRIM Inc., one of our portfolio companies, has been listed on Tokyo Stock Exchange.
-
Listed on Aug. 9, 2019
-
TSE Mothers：4599
IPO
EirGenix, Inc., one of our portfolio companies, has been listed on Taipei Exchange.
-
Listed on Jun. 28, 2019
-
TPEx：6589
Info
Open Innovation Partners, Inc. has received FDA approval.
Investment
We have established Anexa PEP Inc., a biotech company.
Investment
We have established a biotech company and formed a strategic partnership with Mitsubishi Tanabe Pharma.
IPO
ASLAN Pharmaceuticals Limited, one of our portfolio companies, has been listed on Taipei Exchange.
-
Listed on Jun. 1, 2017
-
TPEx：6497
Investment
We have established J-mab Therapeutics, Inc., a biotech company.
Info
The fund size of the Daiwa Taiwan-Japan Biotech Fund Investment Limited Partnership has been increased to 11.6 billion JPY.
Info
DCI Partners will give a speech on July 22nd at Bio Taiwan 2015.
Info